A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
Stopped Due to the significantly lower than expected accrual it was impossible to evaluate the endpoint in a timely fashion.
Conditions
- Stage III (IIIB or IIIC) Colon Cancer
Interventions
- DRUG: Regorafenib
- DRUG: Placebo
Sponsor
NSABP Foundation Inc
Collaborators